Lisata Therapeutics (NASDAQ:LSTA) Stock Price Down 5.1% – What’s Next?

by · The Cerbat Gem

Lisata Therapeutics, Inc. (NASDAQ:LSTA – Get Free Report)’s share price fell 5.1% on Monday. The stock traded as low as $1.50 and last traded at $1.50. Approximately 38,180 shares changed hands during trading, a decline of 88% from the average daily volume of 306,459 shares. The stock had previously closed at $1.58.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Lisata Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Two equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Reduce”.

Get Our Latest Report on LSTA

Lisata Therapeutics Stock Performance

The firm’s 50-day moving average price is $1.47 and its two-hundred day moving average price is $2.98. The stock has a market cap of $13.52 million, a price-to-earnings ratio of -0.91 and a beta of 0.94.

Lisata Therapeutics (NASDAQ:LSTA – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.32) earnings per share (EPS) for the quarter. As a group, sell-side analysts expect that Lisata Therapeutics, Inc. will post -1.09 earnings per share for the current fiscal year.

Institutional Trading of Lisata Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in LSTA. Bank of America Corp DE acquired a new position in Lisata Therapeutics in the second quarter valued at approximately $35,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Lisata Therapeutics during the second quarter worth $157,000. BlackRock Inc. purchased a new stake in Lisata Therapeutics in the second quarter valued at $187,000. GSA Capital Partners LLP purchased a new stake in Lisata Therapeutics in the second quarter valued at $321,000. Finally, Rangeley Capital LLC purchased a new stake in Lisata Therapeutics in the first quarter valued at $376,000. Institutional investors and hedge funds own 8.94% of the company’s stock.

Lisata Therapeutics Company Profile

(Get Free Report)

Lisata Therapeutics, Inc (NASDAQ:LSTA) is a clinical-stage biotechnology company focused on developing therapies for the treatment of cancer. The company’s research is centered on improving the delivery of anticancer agents into solid tumors and addressing the biological barriers that can limit the effectiveness of conventional cancer treatments.

Lisata’s lead investigational product is certepetide, formerly known as LSTA-1. Certepetide is a tumor-penetrating peptide designed to selectively bind to neuropilin-1, a receptor associated with tumor vasculature and the tumor microenvironment.

Featured Stories